+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Live Vaccines market forecast 2020-2030 set to grow to $20,020mn by 2030” says new Visiongain report

13 March 2020
Pharma

Visiongain has launched a new pharma report: Global Live Vaccines Market Bacterial, Viral, Oral Polio Vaccine, Measles, Rotavirus, Tuberculosis, Yellow Fever, Oral, Injectable, End Users, Hospitals, Specialty Clinics, Others.

Live attenuated vaccines contain weakened versions of the live virus to create a protective immune response in healthy individuals. They include vaccines for measles, mumps and rubella (MMR), varicella (chickenpox), Oral Polio Vaccine (OPV) etc. The resurgence of interest in vaccine research has been underpinned by the rapidly expanding body of knowledge in the fields of microbial pathogenesis and immunology. This has advanced the ability of researchers and manufacturers to create both preventive and therapeutic vaccines and target new diseases.

The lead analyst of the report commented "There are a number of innovative vaccines in the pipeline, which will enter the market in the coming decade. Advancements in technology will lead to improvements in the efficacy & coverage of vaccines. The recent rise in global disease outbreaks such as Ebola, Zika, Nipah and 1N1 virus has further increased demand for vaccines and galvanised vaccine advocacy. The Asia Pacific region will be the fastest growing submarket, due to a rise in governments implementing national immunisation policies & public awareness initiatives by organisations like WHO."

Leading companies featured in the report include AstraZeneca, Bavarian Nordic A/S, DAIICHI SANKYO COMPANY, LIMITED, Emergent BioSolutions Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc. & Other Companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

Read

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

Read

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

Read

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever